Yale University Suspends Professor Over Epstein Contacts

Written by Emily J. Thompson, Senior Investment Analyst

Source: CNBC

Updated: Feb 11 2026

0mins

HBIO-3.77%

Should l Buy HBIO?

Source: CNBC

Teaching Suspension: Yale University has suspended Professor David Gelernter from teaching computer science classes while reviewing his contacts with Jeffrey Epstein, indicating the institution's commitment to maintaining professional boundaries in academia.
Email Correspondence Under Scrutiny: Gelernter's extensive email exchanges with Epstein, revealed after the Department of Justice released related files, included references to a Yale student for a potential project, raising concerns about the implications for the university's reputation and the professor's career.
University's Stance on Conduct: A Yale spokesperson emphasized the university's dedication to excellence in the classroom and stated that it does not condone the professor's actions, reflecting a strong institutional commitment to uphold academic integrity and respect.
Historical Context Influencing Decision: Gelernter, who was seriously injured in a 1993 bombing incident, adds a layer of complexity to his public persona, and the university's decision may also be influenced by the historical context of his past experiences.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy HBIO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on HBIO

Wall Street analysts forecast HBIO stock price to rise

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.530

Low

2.00

Averages

2.00

High

2.00

Current: 0.530

Low

2.00

Averages

2.00

High

2.00

Benchmark

Bruce Jackson

Speculative Buy

downgrade

$3 -> $2

2025-09-10

Reason

Benchmark

Bruce Jackson

Price Target

$3 -> $2

AI Analysis

2025-09-10

downgrade

Speculative Buy

Reason

Benchmark analyst Bruce Jackson lowered the firm's price target on Harvard Bioscience to $2 from $3 and keeps a Speculative Buy rating on the shares. Concerns about basic research funding, drug pricing, and tariffs create an uncertain environment for the sector that seems likely to persist for the near future, says the analyst, who cites the heightened risk profile for the firm's lowered target.

Benchmark

Speculative Buy

downgrade

2025-05-13

Reason

Benchmark

Price Target

2025-05-13

downgrade

Speculative Buy

Reason

Benchmark lowered the firm's price target on Harvard Bioscience to $3 from $4.50 and keeps a Speculative Buy rating on the shares. The outlook for end-user markets in biomedical research continues to be challenging due to uncertainty around China tariffs, NIH funding, and biopharmaceutical research activity, which leads the firm to lower its 2025 revenue estimate as a result. However, despite the near-term uncertainty, management remains optimistic about the 2025 prospects for newly launched products, says the analyst, who believes shares could experience multiple expansion if the company continues to execute its plan to grow the business organically, increase cash flow, and pay down debt.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HBIO

Unlock Now

About HBIO

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Harvard Bioscience Announces 1-for-10 Reverse Stock Split

2 days agoNASDAQ.COM

Reverse Stock Split Announcement: Harvard Bioscience has announced a 1-for-10 reverse stock split effective March 13, 2026, reducing the outstanding shares from approximately 44.7 million to 4.47 million, which may impact the company's stock price and market perception.
Stock Price Decline: Following the announcement, HBIO shares fell roughly 12.76% in overnight trading, dropping from $0.55 to $0.47, indicating a negative market reaction and a potential decline in investor confidence.
Authorized Shares Unchanged: The company noted that the reverse split will not alter the total number of authorized shares, and proportional adjustments will be made to outstanding stock options, warrants, and convertible securities to maintain equity fairness among shareholders.
Upcoming Earnings Report: Harvard Bioscience is scheduled to report its fourth-quarter financial results on March 12, 2026, before market open, and investors will closely monitor these results to assess the potential impact of the reverse split on the company's future performance.

Harvard Bioscience Approves 1-for-10 Reverse Stock Split

4 days agoseekingalpha

Reverse Split Decision: Harvard Bioscience approved a 1-for-10 reverse stock split following shareholder authorization at a special meeting on March 6, 2026, aimed at increasing the share price to meet Nasdaq's minimum bid requirement.
Effective Date: The reverse split will take effect on March 13, 2026, reducing the company's outstanding shares from approximately 44.72 million to about 4.47 million, while the total authorized share count will remain unchanged.
Market Reaction: Following the announcement of the reverse split, Harvard Bioscience's shares fell by 4.19%, indicating a cautious market response that may affect investor confidence in the company's future.
Compliance Challenges: The primary goal of this reverse split is to restore compliance with Nasdaq regulations, highlighting the pressures the company faces in the current market environment and its commitment to enhancing shareholder value.

HARVARD BIOSCIENCE DECLARES REVERSE STOCK SPLIT

4 days agomoomoo

Harvard Bioscience Announcement: Harvard Bioscience has announced a reverse stock split to enhance its stock price and attract more investors.
Reason for the Split: The reverse stock split is intended to improve the company's market perception and comply with listing requirements.
Impact on Shareholders: Shareholders will see a reduction in the number of shares they own, but the overall value of their investment should remain the same.
Future Outlook: The company aims to leverage this move to strengthen its financial position and support future growth initiatives.

Harvard Bioscience to Participate in Virtual Healthcare Forum

Mar 03 2026Newsfilter

Executive Participation: Harvard Bioscience's CEO John Duke and Interim CFO Mark Frost will participate in KeyBanc Capital Markets' Virtual Healthcare Forum on March 17, showcasing the company's leadership in life sciences.
Webcast Arrangement: The fireside chat will be broadcast at 2:15 PM ET on the company's investor relations website, allowing global investors and stakeholders to engage, thereby enhancing transparency and interaction.
Company Background: Harvard Bioscience focuses on developing, manufacturing, and selling technologies and products for life science applications, with clients including renowned academic institutions and leading pharmaceutical and biotechnology companies, highlighting its significance in the industry.
Global Business Presence: The company operates in the U.S., Europe, and China, selling through direct and distribution channels to customers worldwide, indicating its extensive influence and business expansion capabilities in international markets.

Harvard Bioscience to Announce Q4 2025 Financial Results

Feb 26 2026Newsfilter

Earnings Announcement Schedule: Harvard Bioscience is set to release its Q4 2025 financial results before the market opens on March 12, 2026, reflecting the company's commitment to transparency and investor communication.
Conference Call Details: The company will hold a conference call at 8:00 a.m. Eastern Time, requiring participants to register in advance to receive dial-in numbers and a unique PIN, ensuring direct engagement in discussions.
Webcast Option: For investors preferring audio-only participation, the company offers a webcast option, enhancing accessibility and interactivity of the information shared during the call.
Company Background: Harvard Bioscience focuses on developing and selling technologies for life science applications, serving a diverse clientele that includes leading academic institutions and pharmaceutical companies, underscoring its significant position and influence in the industry.